Key Takeaways
- Neurologists warn that the same rapid weight loss that makes Ozempic and Wegovy so popular may speed decline in ALS, where keeping weight and muscle is central to treatment.
- A 2025 case report describes a woman who lost 25 pounds in three months on semaglutide as her ALS score fell sharply, then stabilized after she stopped the drug.
- ALS is not on the semaglutide label. The warning comes from doctors watching patients, not from a regulatory alert, which is exactly why they are speaking up.
A good drug in the wrong body
GLP-1 drugs like semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, do one thing extremely well: they make people eat less and lose weight. For type 2 diabetes and obesity that is the whole point, and the payoff extends to heart and liver health too.
But weight loss is not universally good. In amyotrophic lateral sclerosis, it can be dangerous. ALS destroys motor neurons, wastes muscle, and pushes the body into a high-metabolism state that burns through calories. Standard ALS care runs the opposite direction from a diet drug: doctors want patients to hold their weight steady, sometimes even to gain. Drop a drug that aggressively strips weight into that situation and you may be pulling away the very reserve the patient needs.
What the neurologists are saying
Jinsy Andrews, MD, director of NYU Langone’s ALS Center, put the tension plainly: the mechanism that makes these drugs a hit, fast weight loss, runs against the biological needs of people with neuromuscular disease. She is not calling them dangerous drugs. She is saying the patient matters. A GLP-1 that helps a diabetic in one clinic could accelerate deterioration in a diabetic who also has ALS.
Her caution rests on more than intuition. Andrews points to published documentation plus retrospective cohort data on ALS patients with diabetes as growing evidence that clinicians need to think hard about who gets these drugs.
The case that anchors the concern
The clearest example is a case report published in 2025 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. A 52-year-old woman with ALS started semaglutide to manage her type 2 diabetes. Over three months she lost 25 pounds, and across the same stretch her ALS functional score worsened sharply. Her doctors stopped the drug. The rapid slide halted and her condition stabilized.
One case cannot prove the drug caused the decline. Reversibility on stopping is a strong hint, though, and it lines up with the metabolic logic: take weight and muscle from a body already losing both, and you would expect faster loss of function.
What it means in practice
Nobody is saying people with ALS can never take a GLP-1. The message is narrower and more useful: match the drug to the whole patient. Before starting one in someone with ALS or a similar condition, weigh their nutritional status and metabolic demands, keep weight-maintenance goals front and center, and if the drug is genuinely needed for blood sugar, watch weight and function closely rather than assuming loss is a win.
Novo Nordisk, for its part, notes that semaglutide’s prescribing information does not list ALS or other neurodegenerative diseases as adverse reactions, and says it keeps monitoring safety reports. That is the gap Andrews is flagging: the label reflects the trials, and the trials were not built around ALS. Sometimes the warning shows up in a clinic well before it shows up on a package insert.
Sources:
- Fox News Health, “Doctors reveal hidden danger for some Ozempic, Wegovy users with brain disorders”
- New York Post, “Ozempic, Wegovy may pose hidden danger for people with brain disorders, doctors warn”
- Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2025 case report)
Disclaimer: This article is for general information only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider about any medical condition or before making health decisions.